Methotrimeprazine Dosage

Applies to the following strengths: 20 mg/mL

Usual Adult Dose for Anxiety

ORAL:
Minor conditions (e.g., as an analgesic, anxiolytic, sedative, tranquilizer): 6 to 25 mg orally per day, given in 3 divided doses
Severe conditions (e.g., for psychoses or intense pain):

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Depression

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Mania

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Pain

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Psychosis

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Trigeminal Neuralgia

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Schizophrenia

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Nausea/Vomiting

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Neuropathic Pain

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Breakthrough Pain

Initial dose: 50 to 75 mg orally per day, given in divided doses 2 to 3 times per day
Maximum dose: 1000 mg/day

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Adjunct to post-operative analgesic: 10 to 25 mg via IM injection every 8 hours

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Patients requiring initial oral doses of 100 to 200 mg/day should be given the drug in divided doses and should be kept in bed for the first few days.

Uses:

As an adjunct to post-operative analgesia
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomfort
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Treatment of acute schizophrenia
Treatment of chronic schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Adult Dose for Insomnia

ORAL:

Initial dose: 6 to 25 mg orally per day, given in 3 divided doses with meals
Sedative: 10 to 25 mg orally once a day at night

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Comments:

Doses should be determined by the condition and the patient's response.
Initial doses should be increased until an optimal level is achieved.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
Management of insomnia

Usual Adult Dose for Sedation

ORAL:

Initial dose: 6 to 25 mg orally per day, given in 3 divided doses with meals
Sedative: 10 to 25 mg orally once a day at night

PARENTERAL:
Injection: 25 mg via IM injection 3 to 4 times a day

Comments:

Doses should be determined by the condition and the patient's response.
Initial doses should be increased until an optimal level is achieved.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
Management of insomnia

Usual Pediatric Dose for Anxiety

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Depression

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Insomnia

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Mania

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Pain

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Psychosis

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Sedation

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Trigeminal Neuralgia

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Schizophrenia

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Nausea/Vomiting

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Neuropathic Pain

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Usual Pediatric Dose for Breakthrough Pain

ORAL:
Children:

Initial dose: 0.25 mg/kg orally per day, given in 2 to 3 divided doses
Maximum dose: 40 mg/day (in children less than 12 years)

PARENTERAL:
Children:
IM: 0.0625 to 0.125 mg/kg via IM injection once a day or in divided doses

IV: 0.0625 mg/kg via slow IV infusion, at a rate of 20 to 40 drops per minute

Comments:

Use of this drug with regional or spinal anesthesia is contraindicated.
IM injections should be administered deep into a large muscle.
IV formulations should be administered in the context of palliative care.
Doses given concurrently with narcotics should be appropriately reduced.
Doses should be determined by the condition and the patient's response.
If patients experience daytime sedation, a larger portion of the dose may be given in the evening.
Oral formulations should be substituted for parenteral formulations as soon as possible.
Initial doses should be increased until an optimal level is achieved.

Uses:

As a potentiator of anesthetics in general anesthesia for pre- and post-operative sedation and analgesia
As an adjunct to post-operative analgesia
As an analgesic in muscular discomforts
As an analgesic in pain due to cancer
As an analgesic in pain due to muscular discomforts
As an analgesic in pain due to neurocostal neuralgia
As an analgesic in pain due to trigeminal neuralgia
As an analgesic in pain due to zona
As an analgesic in phantom limb pains
Management of insomnia
Treatment of acute schizophrenia
Treatment of conditions associated with anxiety and tension (e.g., autonomic disturbances, emotional disturbances secondary to resistant pruritus and other physical conditions, personality disturbances)
Treatment of chronic schizophrenia
Treatment of manic-depressive syndromes
Treatment of nausea and vomiting of central origin
Treatment of psychotic disturbances
Treatment of senile psychoses

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Contraindicated

Dose Adjustments

Patients with arteriosclerosis or cardiovascular disorders: Patients should begin with low initial treatment doses.

Large initial oral doses: Patients should be kept in bed for the first few days.

Patients taking other phenothiazines and/or central nervous system (CNS) depressants concomitantly: The usual dose of these agent(s) should be decreased by 50% if they are taken concomitantly until the dose of this drug is established.

Parenteral doses for adjunctive post-operative analgesia of 10 to 25 mg every 8 hours are equivalent to 20 to 40 mg oral doses.

Precautions

CONTRAINDICATIONS:

Hypersensitivity to the active component or any of the ingredients
In patients with blood dyscrasias
Liver dysfunction
Patients with brain damage
Patients with central nervous system (CNS) depression or coma due to alcohol, analgesics, hypnotics, or narcotics
Patients with circulatory collapse, severe heart disorder, and/or severe hypotension
Pheochromocytoma
Regional or spinal anesthesia
Sensitivity to phenothiazines

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Continuous subcutaneous infusions should be given with a syringe driver.
Injections may be given via IM or IV.

Storage requirements:

Protect from light

Reconstitution/preparation techniques:

The manufacturer product information should be consulted.

IV compatibility:

Compatible: Normal saline, diamorphine

General:

Limitation of use: This drug should not be used to treat dementia-related behavioral disturbances.
This drug does not significantly decrease respiration, and may be useful in patients with low pulmonary reserve.

Monitoring:

CARDIOVASCULAR: ECG should be considered prior to starting treatment, before dose escalations, and in patients at maximum therapeutic doses
HEMATOLOGIC: Complete blood count (CBC) testing prior to starting treatment, regularly during the first 2 to 3 months after initiation, and periodically thereafter
HEPATIC: Liver function tests should be performed periodically (e.g., at least every 6 to 12 months) in patients receiving long-term treatment
METABOLIC: Glycemic monitoring, especially during initiation; weight monitored regularly during treatment; serum electrolyte levels periodically during chronic treatment

Patient advice:

Inform patients that this drug may cause confusion, disorientation, drowsiness, and/or excessive hypotension, and they should avoid driving or operating machinery if these side effects occur.
Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

More about methotrimeprazine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Migraine 101

Drug Status

Availability Discontinued

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

User Reviews & Ratings

Review this drug

Methotrimeprazine Dosage

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Anxiety

Usual Adult Dose for Depression

Usual Adult Dose for Mania

Usual Adult Dose for Pain

Usual Adult Dose for Psychosis

Usual Adult Dose for Trigeminal Neuralgia

Usual Adult Dose for Schizophrenia

Usual Adult Dose for Nausea/Vomiting

Usual Adult Dose for Neuropathic Pain

Usual Adult Dose for Breakthrough Pain

Usual Adult Dose for Insomnia

Usual Adult Dose for Sedation

Usual Pediatric Dose for Anxiety

Usual Pediatric Dose for Depression

Usual Pediatric Dose for Insomnia

Usual Pediatric Dose for Mania

Usual Pediatric Dose for Pain

Usual Pediatric Dose for Psychosis

Usual Pediatric Dose for Sedation

Usual Pediatric Dose for Trigeminal Neuralgia

Usual Pediatric Dose for Schizophrenia

Usual Pediatric Dose for Nausea/Vomiting

Usual Pediatric Dose for Neuropathic Pain

Usual Pediatric Dose for Breakthrough Pain

Renal Dose Adjustments

Liver Dose Adjustments

Dose Adjustments

Precautions

Dialysis

Other Comments

More about methotrimeprazine

Further information